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CONCLUSIONS: The prevalence of AF in selected countries was forecasted to grow
substantially in both developing and developed countries. As the world’s popula-
tion ages and health care becomesmore accessible, the economic burden of AFwill
continue to rise as well.
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CLINICAL AND ECONOMIC OUTCOMES DERIVED FROM THE USE OF A
CHLORHEXIDINE – IMPREGNATED SPONGE (BIOPATCH®) FOR THE PREVENTION
OF CATHER-RELATED BLOODSTREAM INFECTIONS IN INTENSIVE CARE UNITS
IN MEXICO
Zanela OO, Cabra HA, Rodriguez S, Junqueira SM
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OBJECTIVES: Estimate the expected number of catheter-related bloodstream infec-
tions (CRBSIs) and the associated costs derived from the adoption of a chlorhexi-
dine-impregnated sponge (Biopatch®) plus central venous catheter (CVC) tradi-
tional standard of care strategy in intensive care units (ICUs) versus CVC traditional
standard of care (no sponge) from a Mexican public hospital perspective.
METHODS: A decision tree was developed to estimate the clinical and economic
consequences of adding Biopatch® to CVC traditional standard of care in adult
population. ICUs’ annual catheter-days were estimated using local average occu-
pancy, number of placed catheters and length of stay published statistics. The
effectiveness variable was the CRBSI rate / 1000 catheter days, obtained from pub-
lished literature and used to estimate annual CRBSIs. It was assumed that once a
patient developed a CRBSI, he incurred in additional length of stay and received the
correspondent pharmacologic treatment; only one infection per patient was al-
lowed. Cost data were obtained from published literature and the public institu-
tion’s price data base; the cost for Biopatch® was internally assessed. The consid-
ered time horizonwas one year, thus no annual discount ratewas used. Costs were
inflation-adjusted and expressed in 2011Mexican pesos. Bivariate sensitivity anal-
yses were performed to assess uncertainty. RESULTS: The addition of Biopatch® to
CVC traditional standard of care in ICUs resulted in a 70% reduction of expected
annual CRBSIs and 0.8% less total costs when compared to the traditional standard
of care alone, thus representing a cost-saving alternative. Results were robust to
25% variations in the price of the sponge, ICU occupancy and CRBSI rates, even in
the extreme scenarios. CONCLUSIONS: The adoption of a Biopatch® plus CVC
traditional standard of care strategy in adult population at ICUs results in signifi-
cant clinical and economic benefits for the hospital, as it reduces CRBSI incidence
and resource utilization.
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BYPASS THERAPY ASSAY TESTING AS A STRATEGY TO REDUCE TREATMENT
COSTS FOR HEMOPHILIA PATIENTS WITH INHIBITORS
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OBJECTIVES: Published studies suggest that bypass therapy assay testing can be
used to effectively predict treatment response and dosing requirements for an
individual hemophilia patientwith inhibitors. This study aims to evaluate the costs
and treatment outcomes of bypass therapy assay testing versus no testing strategy
on different treatments for mild to moderate bleeding hemophilia patient with
inhibitors. This study also investigates the cost implications if testing assays could
predict the optimum dose for new type of therapies like concomitant therapy.
METHODS: A decision tree simulation model was used to simulate inhibitor treat-
ment costs and outcomes from a US third party payer perspective. All estimates of
costswere obtained from the literature or expert opinion andwere adjusted to 2011
US dollars. Based on a previous published model, the efficacy of APCC and rFVIIa
were assumed to be the same in the no testing scenario while assay testing was
assumed to improve the efficacy of both the products by 10%. Probabilistic sensi-
tivity analysis was used to determine the robustness of the model’s results. The
model was developed usingMicrosoft Excel and @Risk. RESULTS: If bypass therapy
assay testing successfully predicts the treatment response and improves treat-
ment efficacy by just 10%, cost savings of $6939 for APCC and $7699 for rFVIIa
treatment were observed per bleeding episode. Further, if testing successfully pre-
dicts the optimum dose for concomitant therapy on the onset of bleeding, signifi-
cant cost savings were observed when compared to rFVIIa and APCC therapies
alone. The results were sensitive to frequency of dosing, efficacy, rebleed rate and
drug price. CONCLUSIONS: Bypass therapy assay testing is recommended for re-
ducing costs while optimizing treatment response and dose before administering
treatment in hemophilia patients with inhibitors.
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OBJECTIVES: To compare cost of care among Type II diabetic patients using an
insulin pump delivery system versus alternate methods of insulin delivery (focus
on multiple daily injectors [MDIs]) using administrative claims data. METHODS:
This study used 2009MarketScan®ResearchDatabase data. Patientswere included
if they were continuously enrolled throughout 2009 and were classified as Type II
diabetic based on a combination of diagnosis codes andmedication claimswith the
final application of age where diagnosis was indeterminate. Patients were then
classified as MDIs and insulin pump users based on HCPCS codes and the use of
rapid or short acting insulin prescriptions. Treatment costs were the focus and
included pumps, pump supplies, insulin, and drugs. Costs of complications and
hospitalizations were not included. The study utilized a breakeven analysis to
capture both the fixed and variable costs associated with insulin pumps versus
injection across different cost percentiles of insulin and other drugs. RESULTS: A
total of 68,636 Type II diabetics met inclusion criteria, of which 84% (57,418) were
MDIs, and 16% (11,218) used insulin pumps. Durable insulin pumps required an
upfront investment of approximately $4200 with additional pump supply costs.
Insulin pump users, however, required less insulin and other drugs comparedwith
MDI patients, resulting in less associated costs. Insulin pumps last approximately
four years, and their value proposition increases with the level of insulin use re-
quired. Breakeven analysis revealed patients at the top 10th percentile of expen-
ditures for insulin and other drugs generated savings through lower use of insulin,
which offset the insulin pump cost in 3 years (1,071 days). CONCLUSIONS: Al-
though durable insulin pumps have an upfront cost, they are better able to control
insulin delivery. The reduced drug-related expenditures offset initial pump invest-
ment within three years for the most costly cohort of insulin users.
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ESTIMATED COST SAVING FOR ARTHROSCOPIC SUBACROMIAL
DECOMPRESSION
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OBJECTIVES: To estimate and compare the cost of arthroscopic subacromial de-
compression (SAD) using VAPR®VUE™Radiofrequency Systemwith COOLPULSE®
90 Electrode (COOLPULSE) and the ArthroCare® Quantum™ System with Super
TurboVac® electrode (Super TurboVac).METHODS: An in-vitro study of 72 bovine
tendon specimens was used with COOLPULSE 90 and Super TurboVac. These de-
vices were operated at their default ablation settings (220 and 270Watts for COOL-
PULSE and TurboVac, respectively) for multiple trials. The tissue removal rate was
determined by measuring the tissue mass before and after ablation. The measure
was repeated and averages were calculated. Average length of time needed for
tissue removal in SAD procedures and data on the unit cost of operation room (OR)
time were obtained from clinical model for arthroscopic procedure and published
literature. 2011 IMS data were used to calculate the average selling price for COOL-
PULSE and Super TurboVac. RESULTS: The in-vitro study showed the average ab-
lation rates for COOLPULSE (no clogs were found with COOLPULSE) and Super
TurboVac (excluding data from clogged runs for Super TurboVac) were 1.120.22
gram/minute and 0.930.21 gram/minute, respectively (p  0.001). Average time
for SAD from literature and clinical modeling was 13 minutes and the estimated
cost of OR time in the US was $20/minute. The average costs of ablation using
COOLPULSE and Super TurboVac were estimated to be $436 and $480, respectively.
CONCLUSIONS: Tissue removal rate in arthroscopic procedures is important for
surgical efficiency, for procedure duration that directly benefits patients, and for
cost. The in-vitro study demonstrated that COOLPULSE achieved significantly
higher tissue removal rates compared to Super TurboVac which may result in cost
savings to a surgery facility.
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INDUSTRIAL-GRADE SILICONE IN BREAST IMPLANTS: EVALUATING COST
IMPLICATIONS OF DIFFERENT EXPLANTATION STRATEGIES
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OBJECTIVES: In December 2011, French health authorities agreed to reimburse the
explantation of defective Poly Implant Prothèse (PIP) breast implants, triggering
responses fromother national policymakers. Spurred by public concern andmedia
coverage, the UK health secretary announced that the National Healthcare Service
(NHS) would remove and replace the defective devices it had installed. Using the
UK as a case study, we evaluated three PIP-related policy scenarios that have been
instituted internationally. A cost comparision model was developed to assess the
cost implications of different explantation scenarios and to identify key cost driv-
ers from the perspective of the NHS.METHODS: The model explored the following
scenarios: (a) immediate removal of all PIP breast implants; (b) targeted removal of
ruptured implants; (c) symptom surveillance, with no extraordinary removal of
implants. Complication (e.g. rupture, silicone leakage) rates were taken from the
medical literature. Event management and screening costs were drawn from NHS
Reference Costs (2009-2010). Sensitivity analyses were conducted using a range of
costs, complication rates and patient numbers. RESULTS: Regardless of observed
rupture rates, reimbursing all explantations was the costliest option, followed by
screening and targeted removal of ruptured implants. Given the apparently low
rate of complications, the least costly optionwas a policy of symptom surveillance,
where explantation stemmed from presentation of rupture-related symptoms.
CONCLUSIONS: The dearth of implant-related complication data makes analysis
of the current crisis challenging. Until reliable data about the clinical implications
of the faulty implants are gathered, policymakerswill struggle to accurately assess
the relative budget impact of their recommendations. Even then, heterogeneity
among the devices exported to different countriesmay confound predictions.More
broadly, the lack of complication data highlighted by this study indicates a need for
improved regulation and monitoring of medical devices to ensure future policy
decisions are better informed.
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OBJECTIVES: There has been recent controversy regarding the effectiveness of
vertebral augmentation (balloon kyphoplasty (BKP) and vertebroplasty (VP)) for
treating vertebral compression fractures (VCFs). Limited cost comparisons of BKP
and VP suggest that initial hospital costs are higher for BKP (Mehio 2011), however
costs for subsequent post-operative care are unknown. The present study sought
to characterize and compare the treatment costs for BKP and VP patients through
2 years post-surgery.METHODS:Using the 2005-2009 5%Medicare claims data, BKP
and VP patients were identified using ICD-9-CM and CPT-4 codes. Treatment costs
(Medicare reimbursement/payment adjusted to June 2011 dollars) were compiled
for all components of treatment during the 2-year follow-up. Length of stay (LOS)
and treatment costs for BKP and VP patients were compared using logistic regres-
sion, adjusting for gender, age, census region, comorbidities (Charlson score), race,
socio-economic status (Medicare buy-in status), cancer diagnosis (presence in prior
12 months) and year of surgery. RESULTS: A final cohort of 2878 BKP and 1,609 VP
patients was included. LOS was 3.5 / 4.1 days and 5.5 / 4.3 days for BKP and
VP patients who had inpatient procedures, corresponding to 43% shorted LOS (ad-
justed) for BKP (p0.001). There were no significant differences in average adjusted
treatment costs for BKP and VP patients within the first 3 (p0.097) and first 6
months (p0.142). For the remaining periods, however, BKP patients had lower
adjusted costs (p0.025). At 2 years, the average adjusted costs were 7% lower for
BKP (p0.005). CONCLUSIONS: Although BKP and VP patients in the Medicare pop-
ulation were found to have similar treatment costs within the first six months
following surgery, BKP was found to be cost saving compared to VP subsequently
over time through 2 years.
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OBJECTIVES: To compare clinical and economic outcomes of patients with bone
fracture nonunion receiving non-invasive electrical bone growth stimulator
(EBGS), low-intensity pulsed ultrasound stimulator (LIPUS), or neither stimulation
(No-stim) treatment. METHODS: Medical and pharmacy claims from a U.S. com-
mercially-insured population were analyzed to select patients aged65 who were
newly diagnosedwith nonunion fracture between July 2006 to September 2009. The
date of receiving the first nonunion diagnosis was set as the index date. Three
cohorts were constructed based on the first treatment patients received within
one-year after the index date: EBGS, LIPUS or No-stim. Baseline demographic and
clinical characteristics, and healthcare costs during 9 months before and 1 year
after the index date were assessed. Multivariate regression analyses were per-
formed to compare health care costs incurred in one-year after the index date
between cohorts. RESULTS: A total of 11,628 patients with nonunion fracture
(mean age 45.4 years; 46% males) were identified (EBGS: 29.5%, LIPUS: 12.3%, No-
stim: 58.2%). More than half of the patients (51.8%) had facture-related treatments
in one-year after the index date, and EBGS patients had lower proportion than
LIPUS (37.0% vs. 45.1% , p0.01) and No-stim cohorts (37.0% vs. 60.7%, p0.01).
Patients receiving EBGS were less likely to have at least one hospitalization during
one-year post-index period (14.8% vs. 19.5%, and 14.8% vs. 23.9%, both p0.01).
EBGS cohort had statistically significant lower health care costs in 1-year after
index date than LIPUS (mean: $20,743 vs. $23,271, p0.01) and No-stim cohorts
(mean: $20,743 vs. $24,315, p0.01). Adjusting for variables such as demographic
and clinical characteristics, EBGS patientsmaintained their statistically significant
lower health care costs in one-year after the index date than LIPUS (predicted costs:
$21,632 vs. $23,964, p0.01) and No-stim cohorts (predicted costs: $21,632 vs.
$23,843, p0.01). CONCLUSIONS: Nonunion fracture patients receiving non-inva-
sive electronic stimulation had lower health care costs than patients receiving
ultrasound stimulation or no stimulation.
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COMPARATIVE VALUE ANALYSIS OF TWO ENDOMETRIAL ABLATION
PROCEDURES AMONG PATIENTS SUFFERING FROM MENORRHAGIA
Roy S, Hinoul P
Johnson and Johnson (Ethicon, Inc.), Somerville, NJ, USA
OBJECTIVES: Endometrial ablation has emerged as a minimally invasive alterna-
tive to hysterectomy for pre-menopausal patients suffering from menorrhagia.
Less invasive ablation procedures include thermal balloon endometrial ablation
using GYNECARE THERMACHOICE® III (Ethicon, Inc.), and radio-frequency endo-
metrial ablation using NovaSure® (Hologic, Inc.). This study compares costs of
achieving desired treatment outcomes with Thermachoice versus Novasure abla-
tion techniques.METHODS: A value analysis model was developed to estimate the
cost-per-patient treated with either device – overall, and for achieving desired
treatment outcomes of ‘amenorrhea’, ‘return to normal bleeding’, and ‘patient
satisfaction’. Subsequent hysterectomy was also modeled as a failure outcome.
Costs were included for the ablation device, disposables, operating room (OR) time,
and subsequent hysterectomy. Capital expenditure for controller was included for
Thermachoice, but not for Novasure, to represent a best possible scenario for No-
vasure. Analysis was performed from a hospital buyer perspective, over 1- and 3-
years following initial ablation procedure. Sensitivity analyses were conducted by
forcing reductions in clinical effectiveness and simultaneous increase in subse-
quent hysterectomy for procedure with lesser costs in the base cases. RESULTS:
100 hypothetical patients underwent each procedure. Overall cost-per-patient was
lower for Thermachoice over both 1 and 3 year timeframes – offering a saving of
about 4% compared toNovasure. For specific outcomes, savingswere between 6.9%
for ‘patients achieving amenorrhea’ to 7.8% for ‘patients returning to normal bleed-
ing’ in 1 year and between 3.8% and 4.8% for all outcomes in the 3 year scenario.
Sensitivity analyses showed that Thermachoice continued to offer savings in over-
all cost-per-patient compared to Novasure even with a reduction of all effective-
ness outcomes and increase in subsequent hysterectomy rates by about 50% and
18% in the 1- and 3-year scenarios. CONCLUSIONS: In our model, endometrial
ablation with Thermachoice offered cost savings – compared to Novasure, in
achieving desired short and long term treatment outcomes.
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COMPARISON OF STATISTICAL METHODS USED TO MODEL HEALTH CARE
COSTS BY DIALYSIS MODALITY IN THE TREATMENT OF KIDNEY FAILURE
Chui BKY, Klarenbach S
University of Alberta, Edmonton, AB, Canada
OBJECTIVES: There is controversy regarding the most appropriate method to ana-
lyze cost data. We examined the role of censoring, model fit and assumption vio-
lations in a study determining the costs of dialysis modality for the treatment of
kidney failure.METHODS: All incident dialysis patients from Alberta from 1999 to
2003 were tracked for direct medical costs (inpatient and outpatient costs, physi-
cian claims, and medication costs) for three years using administrative datasets,
and categorized into peritoneal dialysis (PD) only, hemodialysis (HD) only, or mo-
dality switches (HD to PD; PD to HD). Unadjusted censored and uncensored cumu-
lative costs were determined using the non-parametric method of Lin and boot-
strapping. Model fit and assumption violations for alternate covariate adjusted
regression models were assessed through comparison of various approaches (OLS
or GLM regression, log-transformation, smearing), and the optimal approach
identified. RESULTS: Three year adjusted cumulative costs for patients receiving
PD only and HD to PD groups were $58,724 ($44,123-$73,325; 95% confidence inter-
val) and $114,503 ($96,318-$132,688) respectively, andwere significantly lower than
patients receiving HD only $175,996 ($134,787-$217,205) and PD technique failure
patients $173,308 ($147,725-$119,891). Comparison of censored and uncensored
unadjusted total cumulative costs yielded similar results. Covariate adjusted GLM
regression was the best fit for modeling total cumulative costs when compared to
otherOLS andGLMmodels. For cost categorieswith smaller sample sizes (inpatient
costs; n674), GLM models fitted poorly due to kurtosis, and OLS regression on
log-transformed costs with smearing yielded better less biased estimates.
CONCLUSIONS: GLM regression methods for estimating costs performed well
when applied to our analyseswith larger datasets (n1000), but gave biased results
when smaller datasetswere used.Whenmodeling costswith smaller sample sizes,
the most appropriate regression method can be determined through model diag-
nostics.
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COST OF CHEST X-RAY USING ACTIVITY BASED COSTING APPROACH AT
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OBJECTIVES: The purpose of this study was to estimate the cost of chest X-ray by
activity based costing approach. METHODS: Study was conducted at radiology
department, Penang General Hospital, Penang, Malaysia. The activities involved in
producing a chest X-ray in the hospital were first identified through interviewwith
key personnel in the radiology department. Human resource costwas calculated by
multiplying the mean time spent (in minutes) by employees doing specific activity
to their per-minute salaries. The costs of consumables and clinical equipments
were obtained from the procurement section of the radiology department. The cost
of the building was calculated by multiplying the area of space used by the chest
X-ray facility with the unit cost of public building department. Moreover, straight-
line deprecation with a discount rate of 3% was assumed for calculation of equiv-
alent annual costs for building and machines. Cost of electricity was calculated by
multiplying number of kilo watts used by electrical appliance (chest X-ray facility)
in the year 2010 with electricity tariff for Malaysian commercial consumers (MYR
0.31 per kWh). RESULTS: Five activities were identified which were required to
develop one chest X-ray film. Human resource, capital, consumable and electricity
cost was MYR 1.48, MYR 1.98, MYR 2.15 and MYR 0.04, respectively. Total cost of
single chest X-ray was MYR 5.65 (USD 1.75). CONCLUSIONS: By applying ABC ap-
proach, we can havemore detailed and precise estimate of cost for specific activity
or service. Choice of repeating a chest X-ray for a patient can be based on our
findings, when cost is a limiting factor.
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OBJECTIVES: Refractory overactive bladder (OAB) with urge incontinence is an
underdiagnosed condition with substantial burden on the health care system and
patients with diminished quality-of-life. A significant number of patients will fail
conservative treatment with optimized medical-therapy (OMT) and may benefit
from minimally invasive procedures including sacral-neuromodulation (SNM) or
botulinum-toxin (BonT-A). The goal of this study was to estimate the cost-effec-
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